LFB S.A.'s Recombinant Anti-CD20 Monoclonal Antibody is Granted Orphan Drug Status in the USA for Chronic Lymphocytic Leukemia

Published: Aug 26, 2010

LES ULIS, France--(BUSINESS WIRE)--The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orphan Products Development was granted on August 6th, 2010.

Back to news